Nicotinic receptor stimulation protects nigral dopaminergic neurons in rotenone-induced Parkinson's disease models

Journal of Neuroscience Research

Volumn 87, Issue 2, 2009, Pages 576-585

  Takeuchi, Hiroki ^a   Yanagida, Takashi ^b   Inden, Masatoshi ^b   Takata, Kazuyuki ^b   Kitamura, Yoshihisa ^b   Yamakawa, Kentaro ^c   Sewada, Hideyuki ^c   Izumi, Yasuhiko ^a   Yamamoto, Noriyuki ^a   Kihara, Takeshi ^a   Uemura, Kengo ^a   Inoue, Haruhisa ^a   Taniguchi, Takashi ^b   Akaike, Akinori ^a   Takahashi, Ryosuke ^a   Shimohama, Shun ^d  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^c UTANO NATIONAL HOSPITAL   (Japan)

^d SAPPORO MEDICAL UNIVERSITY   (Japan)

Author keywords

Dopaminergic neuron; Neuroprotection; Nicotine; Parkinson's disease; Rotenone

Indexed keywords

ALPHA BUNGAROTOXIN; ANTIPARKINSON AGENT; DIHYDRO BETA ERYTHROIDINE; NICOTINE; NICOTINE TARTRATE; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA4BETA2; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE INHIBITOR; ROTENONE; CHOLINERGIC RECEPTOR STIMULATING AGENT; DOPAMINE; UNCOUPLING PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LOSS; CHOLINERGIC STIMULATION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOTOR DYSFUNCTION; MOUSE; NERVE CELL CULTURE; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA; ANIMAL; ANIMAL BEHAVIOR; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; IMMUNOHISTOCHEMISTRY; METABOLISM; NERVE CELL; PARKINSONISM; PATHOLOGY; WESTERN BLOTTING;

ANIMALS; BEHAVIOR, ANIMAL; BLOTTING, WESTERN; CHOLINERGIC AGENTS; DOPAMINE; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED C57BL; NEURONS; NICOTINE; PARKINSONIAN DISORDERS; RECEPTORS, NICOTINIC; ROTENONE; SUBSTANTIA NIGRA; UNCOUPLING AGENTS;

EID: 62849096879     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.21869     Document Type: Article

References (55)

1. Akaike A, Tamura Y, Yokota T, Shimohama S, Kimura J. 1994. Nicotine-induced protection of cultured cortical neurons against N-methyl-D-aspartate receptor-mediated glutamate cytotoxicity. Brain Res 644:181-187.
2. Baquet Z, Bickford P, Jones K. 2005. Brain-derived neurotrophic factor is required for the establishment of the proper number of dopaminergic neurons in the substantia nigra pars compacta. J Neurosci 25:6251-6259.
3. Betarbet R, Sharer T, MacKenzie G, Garcia-Osuna M, Panov A, Greenamyre J. 2000. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3:1301-1306.
4. Burn D, Emre M, McKeith I, De Deyn P, Aarsland D, Hsu C, Lane R. 2006. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord 21:1899-1907.
5. Champtiaux N, Gotti C, Cordero-Erausquin M, David D, Przybylski C, Léna C, Clementi F, Moretti M, Rossi F, Le Novère N, McIntosh J, Gardier A, Changeux J. 2003. Subunit composition of functional nicotinic receptors in dopaminergic neurons investigated with knock-out mice. J Neurosci 23:7820-7829.
6. Chomczynski P, Sacchi N. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform. extraction. Anal Biochem 162:156-159.
7. Cormier A, Morin C, Zini R, Tillement J, Lagme G. 2003. Nicotine protects rat brain mitochondria against experimental injuries. Neuropharmacology 44:642-652.
8. De Reuck J, De Weweire M, Van Maele G, Santens P. 2005. Comparison of age of onset and development of motor complications between smokers and non-smokers in Parkinson's disease. J Neurol Sci 231:35-39.
9. Du F, Li R, Huang Y, Li X, Le. W. 2005. Dopamine D3 receptor-preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons. Eur J Neurosci 22:2422-2430.
10. Dunnett S, Björklund A. 1999. Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature 399:A32-A39.
11. Egea J, Rosa A, Cuadrado A, García A, López M. 2007. Nicotinic receptor activation by epibatidine induces heme oxygenase-1 and protects chromaffin cells against oxidative stress. J Neurochem 102:1842-1852.
12. Fujita M, Ichise M, Zoghbi S, Liow J, Ghose S, Vines D, Sangare J, Lu J, Cropley V, Iida H, Kim K, Cohen R, Bara-Jimenez W, Ravina B, Innis R. 2006. Widespread decrease of nicotinic acetylcholine receptors in Parkinson's disease. Ann Neurol 59:174-177.
13. Grinevich V, Letchworth S, Lindenberger K, Menager J, Mary V, Sadieva K, Buhlman L, Bohme G, Pradier L, Benavides J, Lukas R, Bencherif M. 2005. Heterologous expression of human α6β4β3αx5 nicotinic acetylcholine receptors: binding properties consistent with their natural expression require quaternary subunit assembly including the α5 subunit. J Pharmacol Exp Ther 312:619-626.
14. Gundersen H, Bendtsen T, Korbo L, Marcussen N, Møller A, Nielsen K, Nyengaard J, Pakkenberg B, Sorensen F, Vesterby A. 1988. Some new, simple and efficient stereological methods and their use in pathological research and diagnosis. APMIS 96:379-394.
15. Höglinger G, Oertel W, Hirsch E. 2006. The rotenone model of parkinsonism - the five years inspection. J Neural Transm Suppl 70:269-272.
16. Inden M, Kitamura Y, Takeuchi H, Yanagida T, Takata K, Kobayashi Y, Taniguchi T, Yoshimoto K, Kaneko M, Okuma Y, Taira T, Ariga H, Shimohama S. 2007. Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone. J Neurochem 101:1491-1504.
17. Iravani M, Haddon C, Cooper J, Jenner P, Schapira A. 2006. Pramipexole protects against MPTP toxicity in non-human primates. J Neurochem 96:1315-1321.
18. Jeyarasasingam G, Tompkins L, Quik M. 2002. Stimulation of non-α7 nicotinic receptors partially protects dopaminergic neurons from 1-methyl-4-phenylpyndinium-induced toxicity in culture. Neuroscience 109:275-285.
19. Kagitani F, Uchida S, Hotta H, Sato A. 2000. Effects of nicotine on blood flow and delayed neuronal death following intermittent transient ischemia in rat hippocampus. Jpn J Physiol 50:585-595.
20. Khwaja M, McCormack A, McIntosh J, Di Monte D, Quik M. 2007. Nicotine partially protects against paraquat-induced nigrostriatal damage in mice; link to alpha6beta2* nAChRs. J Neurochem 100:180-190.
21. Kihara T, Shimohama S, Sawada H, Kimura J, Kume T, Kochiyama H, Maeda T, Akaike A. 1997. Nicotinic receptor stimulation protects neurons against beta-amyloid toxicity. Ann Neurol 42:159-163.
22. Kihara T, Shimohama S, Sawada H, Honda K, Nakamizo T, Shibasaki H, Kume T, Akaike A. 2001. α7 nicotinic receptor transduces signals to phosphatidylinositol 3-kinase to block Abeta-amyloid-induced neurotoxicity. J Biol Chem 276:13541-13546.
23. Kihara T, Shimohama S, Sawada H, Honda K, Nakamizo T, Kanki R, Yamashita H, Akaike A. 2002. Protective effect of dopamine D2 agonists in cortical neurons via the phosphatidylinositol 3 kinase cascade. J Neurosci Res 70:274-282.
24. Lapointe N, St-Hilaire M, Martinoli M, Blanchet J, Gould P, Rouillard C, Cicchetti F. 2004. Rotenone induces non-specific central nervous system and systemic toxicity. FASEB J 18:717-719.
25. Liu Q, Zhang J, Zhu H, Qin C, Chen Q, Zhao B. 2007. Dissecting the signaling pathway of nicotine-mediated neuroprotection in a mouse Alzheimer disease model. FASEB J 21:61-73.
26. Martínez-Rodríguez R, Toledano A, Alvarez M, Turégano L, Colman O, Rosés P, Gómez de Segura I, De Miguel E. 2003. Chronic nicotine administration increases NGF-like immunoreactivity in frontoparietal cerebral cortex. J Neurosci Res 73:708-716.
27. Mann V, Cooper J, Krige D, Daniel S, Schapira A, Marsden C. 1992. Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. Brain 115(Pt 2):333-342.
28. Mentis M, Delalot D, Naqvi H, Gordon M, Gudesblatt M, Edwards C, Donatelli L, Dhawan V, Eidelberg D. 2006. Anticholinesterase effect on motor kinematic measures and brain activation in Parkinson's disease. Mov Disord 21:549-555.
29. Miyasaki J, Shannon K, Voon V, Ravina B, Kleiner-Fisman G, Anderson K, Shulman L, Gronseth G, Weiner W;Quality Standards Subcommittee of the American Academy of Neurology. 2006. Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66:996-1002.
30. Mizuno Y, Yoshino H, Ikebe S, Hattori N, Kobayashi T, Shimoda-Matsubayashi S, Matsumine H, Kondo T. 1998. Mitochondrial dysfunction in Parkinson's disease. Ann Neurol 44(3 Suppl 1):S99-S109.
31. Morens D, Grandinetti A, Reed D, White L, Ross G. 1995. Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue? Neurology 45:1041-1051.
32. Nakamizo T, Kawamata J, Yamashita H, Kanki R, Kihara T, Sawada H, Akaike A, Shimohama S. 2005. Stimulation of nicotinic acetylcholine receptors protects motor neurons. Biochem Biophys Res Commun 330:1285-1289.
33. O'Neill M, Murray T, Lakies V, Visanji N, Duty S. 2002. The role of neuronal nicotinic acetylcholine receptors in acute and chronic neurodegeneration. Curr Drug Targets CNS Neurol Disord 1:399-411.
34. Parain K, Hapdey C, Rousselet E, Marchand V, Dumery B, Hirsch E. 2003. Cigarette smoke and nicotine protect dopaminergic neurons against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Parkinsonian toxin. Brain Res 984:224-232.
35. Park H, Lee P, Ahn Y, Choi Y, Lee G, Lee D, Chung E, Jin B. 2007. Neuroprotective effect of nicotine on dopaminergic neurons by anti-inflammatory action. Eur J Neurosci 26:79-89.
36. Parker W Jr, Boyson S, Parks J. 1989. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol 26:719-723.
37. Parkinson Study Group. 2006. Randomized placebo-controlled study of the nicotinic agonist SIB-1508Y in Parkinson disease. Neurology 66:408-410.
38. Quik M. 2004. Smoking, nicotine and Parkinson's disease. Trends Neurosci 27:561-568.
39. Quik M, McIntosh J. 2006. Striatal alpha6* nicotinic acetylcholine receptors: potential targets for Parkinson's disease therapy. J Pharmacol Exp Ther 316:481-489.
40. Quik M, Chen L, Parameswaran N, Xie X, Langston J, McCallum S. 2006. Chronic oral nicotine normalizes dopaminergic function and synaptic plasticity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridinelesioned primates. J Neurosci 26:4681-4689.
41. Quik M, Cox H, Parameswaran N, O'Leary K, Langston J, Di Monte D. 2007a. Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys. Ann Neurol 62:588-596.
42. Quik M, O'Neill M, Perez X. 2007b. Nicotine neuroprotection against nigrostriatal damage: importance of the animal model. Trends Pharmacol Sci 28:229-235.
43. Ravenstijn P, Merlini M, Hameetman M, Murray T, Ward M, Lewis H, Ball G, Mottart C, de Ville de Goyet C, Lemarchand T, van Belle K, O'Neill M, Danhof M, de Lange E. 2008. The exploration of rotenone as a toxin for inducing Parkinson's disease in rats, for application in BBB transport and PK-PD experiments. J Pharmacol Toxicol Methods 57:114-130.
44. Rozas G, Liste I, Guerra M, Labandeira-Garcia J. 1998. Sprouting of the serotonergic afferents into striatum after selective lesion of the dopaminergic system by MPTP in adult mice. Neurosci Lett 245:151-154.
45. Santos M, Alkondon M, Pereira E, Aracava Y, Eisenberg H, Maelicke A, Albuquerque E. 2002. The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system. Mol Pharmacol 61:1222-1234.
46. Sawada H, Kohno R, Kihara T, Izumi Y, Sakka N, Ibi M, Nakanishi M, Nakamizo T, Yamakawa K, Shibasaki H, Yamamoto N, Akaike A, Inden M, Kitamura Y, Taniguchi T, Shimohama S. 2004. Proteasome mediates dopaminergic neuronal degeneration, and its inhibition causes alpha-synuclein inclusions. J Biol Chem 279:10710-10719.
47. Schapira A. 2006. Etiology of Parkinson's disease. Neurology 66(10 Suppl 4):S10-S23.
48. Schmidt W, Alam M. 2006. Controversies on new animal models of Parkinson's disease pro and con: the rotenone model of Parkinson's disease (PD). J Neural Transm Suppl 70:273-276.
49. Shimohama S, Greenwald D, Shafron D, Akaike A, Maeda T, Kaneko S, Kimura J, Simpkins C, Day A, Meyer E. 1998. Nicotinic α7 receptors protect against glutamate neurotoxicity and neuronal ischemic damage. Brain Res 779:359-363.
50. Shimohama S, Sawada H, Kitamura Y, Taniguchi T. 2003. Disease model: Parkinson's disease. Trends Mol Med 9:360-365.
51. Suzuki T, Hide I, Matsubara A, Hama C, Harada K, Miyano K, Andrä M, Matsubayashi H, Sakai N, Kohsaka S, Inoue K, Nakata Y. 2006. Microglial α7 nicotinic acetylcholine receptors drive a phospholipase C/IP3 pathway and modulate the cell activation toward a neuroprotective role. J Neurosci Res 83:1461-1470.
52. Visanji N, O'Neill M, Duty S. 2006. Nicotine, but neither the alpha4-beta2 ligand RJR2403 nor an alpha7 nAChR subtype selective agonist, protects against a partial 6-hydroxydopamine lesion of the rat median forebrain bundle. Neuropharmacology 51:506-516.
53. West M, Slomianka L, Gundersen J. 1991. Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anat Rec 231:482-497.
54. Wirdefeldt K, Gatz M, Pawitan Y, Pedersen N. 2005. Risk and protective factors for Parkinson's disease: a study in Swedish twins. Ann Neurol 57:27-33.
55. Xie Y, Bezard E, Zhao B. 2005. Investigating the receptor-independent neuroprotective mechanisms of nicotine in mitochondria. J Biol Chem 280:32405-32412.